Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): A randomized, double-blind, phase III trial

Michael DeGregorio, Lin Soe, Michael Wolf

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint Dive into the research topics of 'Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): A randomized, double-blind, phase III trial'. Together they form a unique fingerprint.